Month: January 2023

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), today announced the 2023 OTCQX® Best 50, a ranking of the top-performing OTCQX companies in the prior calendar year. The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX Best Market, based on an equal weighting of one-year total return and average daily dollar volume growth. Companies in the 2023 OTCQX Best 50 were ranked based on their performance during the 2022 calendar year. “We congratulate the 2023 OTCQX Best 50 companies on being able to outperform their peers in a year of difficult market conditions,” said Jason Paltrowitz, OTC Markets Group EVP of Corporate Services. “This year’s roster represents the breadth of industries and geographies that contribute to the diverse range of OTCQX-traded...

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI–2620 for Alzheimer’s DiseaseFirst Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trial PI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated Tau Tau accumulation, a key Alzheimer’s disease pathology, correlates with cognitive impairmentLausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its collaboration partner, Life Molecular Imaging (LMI), has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET (positron emission tomography) imaging agent for AD (Alzheimer’s disease). PI-2620...

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic. “The addition of NUZYRA to China’s NRDL means millions of patients now benefit from increased accessibility to this life-saving therapy for serious community-acquired...

Vancouver, Jan. 18, 2023 (GLOBE NEWSWIRE) —As announced on 14 December 2022, Victory’s Exploration Team has completed an on-site geological program to finalize the location of drill holes, building upon its previously reported comprehensive effort to delineate significant lithium mineralization on the Smokey Lithium Property Drill hole locations have been selected to extend strong lithium mineralization intersected previously on the property in hole 09 within the area of interest outlined in detail in the Company’s press release dated 20 October 2022 The Company has now amended and submitted its drill permit application with the newly identified hole locations in this new area of interest contiguous with the southwest part of the original claim blockVANCOUVER, BC, CANADA (18 January 2023) – Victory Battery Metals (CSE:...

Figure Initial treatment imaging from first patient treated in the ReSPECT-GBM Phase 2b trialAUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b dose expansion clinical trial evaluating rhenium (186Re) obisbemeda for the treatment of recurrent glioblastoma (GBM). This Phase 2b multi-center trial is designed to evaluate the safety, tolerability, distribution and efficacy of rhenium (186Re) obisbemeda infused directly into the tumor via convection-enhanced delivery catheters in patients with recurrent GBM progressing after conventional treatment. “In...

All dollar amounts are in US$ VANCOUVER, British Columbia, Jan. 18, 2023 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide 2023 production and costs guidance for its Bomboré Gold Mine (“Bomboré”) in Burkina Faso. This marks the Company’s first full year as an operating gold producer after declaring commercial production on December 1, 2022. For 2023, the Company forecasts gold production in the range of 140,000 to 155,000 ounces at an all-in sustaining costs1 (“AISC”) of $975 to $1,075 per ounce sold. Capital expenditures are expected to total between $43 to $49 million as the Company invests in growth projects to improve the future cost structure and mine life of the Bomboré operation. Patrick Downey, President and CEO commented, “Our 2023 guidance builds on...

Stantec commences mineral resource update work programFigure 1 Locations of drill hole collars for results reported January 18, 2023, for Phase 2 of the Calico Project 2022 Drill Program.Figure 2 Cross section of silver results for drill holes W22-RC-042 and W22-RC-047 as reported January 18, 2023, for Phase 2 of the Calico Project 2022 Drill Program.Figure 3 Cross section of silver results in select drill holes as reported January 18, 2023, for Phase 2 of the Calico Project 2022 Drill Program.VANCOUVER, British Columbia, Jan. 18, 2023 (GLOBE NEWSWIRE) — Apollo Silver Corp. (“Apollo” or the “Company”) (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to report additional assay results from the recently completed Phase 2 of the 2022 Drill Program at the Calico Silver Project (“Calico” or the “Project”) located in San...

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommendation from its safety review committee to advance to the fifth dose level (650 mg/m2) in its camsirubicin Phase 1b trial in patients with advanced soft tissue sarcoma (ASTS). This decision was made following a review of safety data from the patients in the first four dose cohorts. “Clearance to go to this higher dose level is an important milestone for the trial as this class of drugs is known to have dose-dependent anti-tumor activity,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “We continue to see a favorable safety...

Producer of plant-based, 100% vegan beverages and related products launches three month experiential marketing collaboration at the XMarket flagship retail location in Venice Beach, CA VANCOUVER, British Columbia, Jan. 18, 2023 (GLOBE NEWSWIRE) — PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) (“PlantX” or the “Company”), the digital face of the plant-based community, operating a one-stop shop for plant-based products, today announced a new collaboration with Minor Figures, a leading producer of plant-based, 100% vegan beverages and oat milk, at its flagship XMarket retail store in Venice Beach, California. HighlightsMinor Figures is debuting a gingersnap latte in partnership with Olympia Coffee Roaster, available exclusively at the Venice location. The brand is also 100% powering the in store coffee shop. There...

BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated January 17, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). As previously announced, the Company was notified by Nasdaq on October 28, 2022 that the Company was not in compliance with...